1. �ൺ��ѧ����ҽԺƤ����
2. �й�ҽѧ��ѧԺƤ�����о���
3. �й�ҽѧ��ѧԺ����Э��ҽѧԺƤ�����о���

��ժҪ�� ���Ժ�������һ����������������ͬ������λ��ͬ��֯ѧ���ͣ����ܴ��ڲ�ͬ�Ļ�����ź�ת��;�����쳣����ˣ�����쳣�����ź�ͨ·�İ�������ҩ��ķ������ٴ�Ӧ��Ϊ���ں��������ߵĸ��Ի������ṩ���µ�ѡ���й�������ĺ�������֫���ͣ����ͺ�������������쳣������c?۲kit�������c?۲kit����İ���ҩ���Ұ��ἤø���Ƽ����������ں������������н϶������о����ٴ��۲졣��Ҫ�����Ұ��ἤø���Ƽ��е������Ұ��ἤø���Ƽ�����е��Ұ��ἤø���Ƽ��ͷ������Ұ��ἤø���Ƽ�3��ҩ���ҩ�����û��Ƽ����������ƺ��������о���չ���Լ��Ұ��ἤø���Ƽ��ij���������Ӧ��

Zhou Lu, Chen Hao*, Sun Jianfang. *Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing 210042, China Corresponding authors: Chen Hao, Email: ch76ch@163.com; Sun Jianfang, Email: sunjf57@163.com ��Abstract�� Malignant melanoma is a heterologous tumor, and abnormalities in different genes and signal transduction pathways may result in malignant melanoma at different body sites and of different histopathological types. Development and clinical application of drugs targeting abnormal genes and signaling pathways provide new options for individualized treatment of patients with advanced melanoma. Acral melanoma is the most common type of melanoma in Chinese population, and c-kit gene is the most common abnormal gene in acral melanoma. There have been many in vitro studies and clinical observations on tyrosine kinase inhibitors ��TKIs�� targeting the c-kit gene for the treatment of patients with advanced melanoma. This review mainly introduces pharmacologic actions of 3 types of TKIs, including receptor TKIs, multitargeted TKIs and nonreceptor TKIs, as well as domestic and international advances in melanoma therapy and common adverse reactions to TKIs.

������Ȼ��ѧ����